Resverlogix Corp. (TSE:RVX – Get Free Report) shares passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$0.10 and traded as high as C$0.12. Resverlogix shares last traded at C$0.12, with a volume of 59,638 shares changing hands.
Resverlogix Stock Performance
The company has a market cap of C$33.04 million, a PE ratio of -3.83 and a beta of 0.93. The company has a debt-to-equity ratio of -10.95, a quick ratio of 0.04 and a current ratio of 0.13. The stock’s 50-day simple moving average is C$0.10 and its 200 day simple moving average is C$0.09.
Resverlogix (TSE:RVX – Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The biotechnology company reported C$0.00 earnings per share (EPS) for the quarter. As a group, equities analysts anticipate that Resverlogix Corp. will post -0.22 EPS for the current year.
About Resverlogix
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Recommended Stories
- Five stocks we like better than Resverlogix
- What Are the U.K. Market Holidays? How to Invest and Trade
- Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Five Below and Dollar Tree Earnings Signal a Shopper Shift
- 3 Tickers Leading a Meme Stock Revival
- Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
